Subjects enrolled, n=1646

Discontinuations, n=267 (16.2%)
Lost to follow-up; n=105 (6.4%)
Received palivizumab after enrollment, n=63 (3.8%)
Changed provider, n=59 (3.6%)
Site withdrawal from study, n=20 (1.2%)
Relocation, n=7 (0.4%)
Withdrawal of consent, n=3 (0.2%)
Protocol violation, n=3 (0.2%)
Death, n=2 (0.1%)
Other, n=5 (0.3%)

Completed study, n=1379 (83.8%)